vs
Side-by-side financial comparison of Ameris Bancorp (ABCB) and Amphastar Pharmaceuticals, Inc. (AMPH). Click either name above to swap in a different company.
Ameris Bancorp is the larger business by last-quarter revenue ($314.4M vs $183.1M, roughly 1.7× Amphastar Pharmaceuticals, Inc.). Ameris Bancorp runs the higher net margin — 35.1% vs 13.3%, a 21.8% gap on every dollar of revenue. On growth, Ameris Bancorp posted the faster year-over-year revenue change (10.0% vs -1.8%). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 2.3%).
Ameris Bancorp is an American bank holding company headquartered in Atlanta, Georgia. Through its bank subsidiary, Ameris Bank, the company operates full-service branches in Georgia, Alabama, Florida, North Carolina and South Carolina, and mortgage-only locations in Georgia, Alabama, Florida, North Carolina, South Carolina, Virginia, Maryland, and Tennessee. The company offers online and mobile banking options for both consumers and businesses.
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
ABCB vs AMPH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $314.4M | $183.1M |
| Net Profit | $110.5M | $24.4M |
| Gross Margin | — | 46.8% |
| Operating Margin | — | 19.4% |
| Net Margin | 35.1% | 13.3% |
| Revenue YoY | 10.0% | -1.8% |
| Net Profit YoY | — | -35.7% |
| EPS (diluted) | $1.63 | $0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $314.4M | — | ||
| Q4 25 | $307.1M | $183.1M | ||
| Q3 25 | $314.2M | $191.8M | ||
| Q2 25 | $300.7M | $174.4M | ||
| Q1 25 | $285.9M | $170.5M | ||
| Q4 24 | $290.8M | $186.5M | ||
| Q3 24 | $283.8M | $191.2M | ||
| Q2 24 | $300.6M | $182.4M |
| Q1 26 | $110.5M | — | ||
| Q4 25 | $108.4M | $24.4M | ||
| Q3 25 | $106.0M | $17.4M | ||
| Q2 25 | $109.8M | $31.0M | ||
| Q1 25 | $87.9M | $25.3M | ||
| Q4 24 | $94.4M | $38.0M | ||
| Q3 24 | $99.2M | $40.4M | ||
| Q2 24 | $90.8M | $37.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 46.8% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 49.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | 46.5% | ||
| Q3 24 | — | 53.3% | ||
| Q2 24 | — | 52.2% |
| Q1 26 | — | — | ||
| Q4 25 | 45.9% | 19.4% | ||
| Q3 25 | 43.6% | 13.2% | ||
| Q2 25 | 47.4% | 24.2% | ||
| Q1 25 | 39.5% | 21.9% | ||
| Q4 24 | 43.3% | 24.2% | ||
| Q3 24 | 44.4% | 29.8% | ||
| Q2 24 | 42.1% | 30.3% |
| Q1 26 | 35.1% | — | ||
| Q4 25 | 44.2% | 13.3% | ||
| Q3 25 | 33.7% | 9.0% | ||
| Q2 25 | 36.5% | 17.8% | ||
| Q1 25 | 30.8% | 14.8% | ||
| Q4 24 | 42.5% | 20.4% | ||
| Q3 24 | 35.0% | 21.1% | ||
| Q2 24 | 30.2% | 20.8% |
| Q1 26 | $1.63 | — | ||
| Q4 25 | $1.59 | $0.51 | ||
| Q3 25 | $1.54 | $0.37 | ||
| Q2 25 | $1.60 | $0.64 | ||
| Q1 25 | $1.27 | $0.51 | ||
| Q4 24 | $1.35 | $0.74 | ||
| Q3 24 | $1.44 | $0.78 | ||
| Q2 24 | $1.32 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $282.8M |
| Total DebtLower is stronger | — | $608.7M |
| Stockholders' EquityBook value | $4.1B | $788.8M |
| Total Assets | $28.1B | $1.6B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $282.8M | ||
| Q3 25 | — | $276.2M | ||
| Q2 25 | — | $231.8M | ||
| Q1 25 | — | $236.9M | ||
| Q4 24 | — | $221.6M | ||
| Q3 24 | — | $250.5M | ||
| Q2 24 | — | $217.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $608.7M | ||
| Q3 25 | — | $608.6M | ||
| Q2 25 | — | $607.7M | ||
| Q1 25 | — | $603.9M | ||
| Q4 24 | — | $601.6M | ||
| Q3 24 | — | $596.4M | ||
| Q2 24 | — | $586.9M |
| Q1 26 | $4.1B | — | ||
| Q4 25 | $4.1B | $788.8M | ||
| Q3 25 | $4.0B | $776.7M | ||
| Q2 25 | $3.9B | $757.5M | ||
| Q1 25 | $3.8B | $751.3M | ||
| Q4 24 | $3.8B | $732.3M | ||
| Q3 24 | $3.7B | $727.7M | ||
| Q2 24 | $3.6B | $713.3M |
| Q1 26 | $28.1B | — | ||
| Q4 25 | $27.5B | $1.6B | ||
| Q3 25 | $27.1B | $1.7B | ||
| Q2 25 | $26.7B | $1.6B | ||
| Q1 25 | $26.5B | $1.6B | ||
| Q4 24 | $26.3B | $1.6B | ||
| Q3 24 | $26.4B | $1.5B | ||
| Q2 24 | $26.5B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.77× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | 0.82× | ||
| Q2 24 | — | 0.82× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $32.9M |
| Free Cash FlowOCF − Capex | — | $24.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | — | 4.5% |
| Cash ConversionOCF / Net Profit | — | 1.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | $121.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $390.2M | $32.9M | ||
| Q3 25 | $104.9M | $52.6M | ||
| Q2 25 | $61.4M | $35.6M | ||
| Q1 25 | $116.9M | $35.1M | ||
| Q4 24 | $154.2M | $29.0M | ||
| Q3 24 | $102.2M | $60.0M | ||
| Q2 24 | $-97.1M | $69.1M |
| Q1 26 | — | — | ||
| Q4 25 | $369.6M | $24.6M | ||
| Q3 25 | $100.5M | $47.2M | ||
| Q2 25 | $53.7M | $25.0M | ||
| Q1 25 | $114.2M | $24.4M | ||
| Q4 24 | $140.7M | $16.6M | ||
| Q3 24 | $99.8M | $46.2M | ||
| Q2 24 | $-100.3M | $63.1M |
| Q1 26 | — | — | ||
| Q4 25 | 120.4% | 13.4% | ||
| Q3 25 | 32.0% | 24.6% | ||
| Q2 25 | 17.9% | 14.3% | ||
| Q1 25 | 39.9% | 14.3% | ||
| Q4 24 | 48.4% | 8.9% | ||
| Q3 24 | 35.2% | 24.1% | ||
| Q2 24 | -33.4% | 34.6% |
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 4.5% | ||
| Q3 25 | 1.4% | 2.8% | ||
| Q2 25 | 2.5% | 6.1% | ||
| Q1 25 | 0.9% | 6.3% | ||
| Q4 24 | 4.6% | 6.7% | ||
| Q3 24 | 0.8% | 7.2% | ||
| Q2 24 | 1.1% | 3.3% |
| Q1 26 | — | — | ||
| Q4 25 | 3.60× | 1.35× | ||
| Q3 25 | 0.99× | 3.03× | ||
| Q2 25 | 0.56× | 1.15× | ||
| Q1 25 | 1.33× | 1.39× | ||
| Q4 24 | 1.63× | 0.76× | ||
| Q3 24 | 1.03× | 1.48× | ||
| Q2 24 | -1.07× | 1.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCB
Segment breakdown not available.
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
